These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15701837)

  • 21. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides.
    Kirkpatrick DL; Kuperus M; Dowdeswell M; Potier N; Donald LJ; Kunkel M; Berggren M; Angulo M; Powis G
    Biochem Pharmacol; 1998 Apr; 55(7):987-94. PubMed ID: 9605422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamic contrast-enhanced MRI measurements of passive permeability through blood retinal barrier in diabetic rats.
    Berkowitz BA; Roberts R; Luan H; Peysakhov J; Mao X; Thomas KA
    Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2391-8. PubMed ID: 15223822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Thioredoxin-1 Inhibitor, PX-12, Suppresses Local Osteosarcoma Progression.
    Kinoshita H; Shimozato O; Ishii T; Kamoda H; Hagiwara Y; Ohtori S; Yonemoto T
    Anticancer Res; 2021 Dec; 41(12):6013-6021. PubMed ID: 34848455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.
    Wu X; Jeong EK; Emerson L; Hoffman J; Parker DL; Lu ZR
    Mol Pharm; 2010 Feb; 7(1):41-8. PubMed ID: 19958031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.
    Ramanathan RK; Kirkpatrick DL; Belani CP; Friedland D; Green SB; Chow HH; Cordova CA; Stratton SP; Sharlow ER; Baker A; Dragovich T
    Clin Cancer Res; 2007 Apr; 13(7):2109-14. PubMed ID: 17404093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody.
    Yuan F; Chen Y; Dellian M; Safabakhsh N; Ferrara N; Jain RK
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14765-70. PubMed ID: 8962129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia inducible factor-1α inhibition produced anti-allodynia effect and suppressed inflammatory cytokine production in early stage of mouse complex regional pain syndrome model.
    Hsiao HT; Lin YC; Wang JC; Tsai YC; Liu YC
    Clin Exp Pharmacol Physiol; 2016 Mar; 43(3):355-9. PubMed ID: 26711019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
    Rudin M; McSheehy PM; Allegrini PR; Rausch M; Baumann D; Becquet M; Brecht K; Brueggen J; Ferretti S; Schaeffer F; Schnell C; Wood J
    NMR Biomed; 2005 Aug; 18(5):308-21. PubMed ID: 15918178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The redox protein thioredoxin-1 (Trx-1) increases hypoxia-inducible factor 1alpha protein expression: Trx-1 overexpression results in increased vascular endothelial growth factor production and enhanced tumor angiogenesis.
    Welsh SJ; Bellamy WT; Briehl MM; Powis G
    Cancer Res; 2002 Sep; 62(17):5089-95. PubMed ID: 12208766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantifying angiogenesis in VEGF-enhanced tissue-engineered bladder constructs by dynamic contrast-enhanced MRI using contrast agents of different molecular weights.
    Cheng HL; Wallis C; Shou Z; Farhat WA
    J Magn Reson Imaging; 2007 Jan; 25(1):137-45. PubMed ID: 17139634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reversible inhibition of human thioredoxin reductase activity by cytotoxic alkyl 2-imidazolyl disulfide analogues.
    Oblong JE; Chantler EL; Gallegos A; Kirkpatrick DL; Chen T; Marshall N; Powis G
    Cancer Chemother Pharmacol; 1994; 34(5):434-8. PubMed ID: 8070012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model.
    Marzola P; Degrassi A; Calderan L; Farace P; Crescimanno C; Nicolato E; Giusti A; Pesenti E; Terron A; Sbarbati A; Abrams T; Murray L; Osculati F
    Clin Cancer Res; 2004 Jan; 10(2):739-50. PubMed ID: 14760097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Evaluation of Antivascular Cancer Therapy Using Constrained Tracer-Kinetic Modeling for Multiagent Dynamic Contrast-Enhanced MRI.
    Hectors SJ; Jacobs I; Lok J; Peters J; Bussink J; Hoeben FJ; Keizer HM; Janssen HM; Nicolay K; Schabel MC; Strijkers GJ
    Cancer Res; 2018 Mar; 78(6):1561-1570. PubMed ID: 29317433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Redox active disulfides: the thioredoxin system as a drug target.
    Kirkpatrick DL; Ehrmantraut G; Stettner S; Kunkel M; Powis G
    Oncol Res; 1997; 9(6-7):351-6. PubMed ID: 9406241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media.
    Pradel C; Siauve N; Bruneteau G; Clement O; de Bazelaire C; Frouin F; Wedge SR; Tessier JL; Robert PH; Frija G; Cuenod CA
    Magn Reson Imaging; 2003 Oct; 21(8):845-51. PubMed ID: 14599534
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome.
    Seshadri M; Spernyak JA; Maiery PG; Cheney RT; Mazurchuk R; Bellnier DA
    Neoplasia; 2007 Feb; 9(2):128-35. PubMed ID: 17356709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.
    Checkley D; Tessier JJ; Kendrew J; Waterton JC; Wedge SR
    Br J Cancer; 2003 Nov; 89(10):1889-95. PubMed ID: 14612898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts.
    Bhujwalla ZM; Artemov D; Natarajan K; Ackerstaff E; Solaiyappan M
    Neoplasia; 2001; 3(2):143-53. PubMed ID: 11420750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting Thioredoxin System with an Organosulfur Compound, Diallyl Trisulfide (DATS), Attenuates Progression and Metastasis of Triple-Negative Breast Cancer (TNBC).
    Liu Y; Zhao Y; Wei Z; Tao L; Sheng X; Wang S; Chen J; Ruan J; Liu Z; Cao Y; Shan Y; Wang A; Chen W; Lu Y
    Cell Physiol Biochem; 2018; 50(5):1945-1963. PubMed ID: 30396169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of metabolic oxidative stress-induced cytotoxicity by the thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide is mediated through the ASK1-SEK1-JNK1 pathway.
    Lee YJ; Kim JH; Chen J; Song JJ
    Mol Pharmacol; 2002 Dec; 62(6):1409-17. PubMed ID: 12435809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.